Neuropace Inc (NPCE)

Nov 25, 2024

NeuroPace's SWOT analysis: epilepsy device maker's stock poised for growth - Investing.com

Nov 25, 2024

Nov 25, 2024

NeuroPace, Inc. (NASDAQ:NPCE) Receives $14.60 Average PT from Analysts - MarketBeat

Nov 25, 2024

Nov 21, 2024

NeuroPace, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 21, 2024

Nov 21, 2024

Top 10 Deep Brain Stimulation Device Companies | Provides Best DevicesMarket.us Media - Market.us Media - United States Market News

Nov 21, 2024

Nov 21, 2024

NeuroPace (NASDAQ:NPCE) versus Cerus (NASDAQ:CERS) Financial Analysis - Defense World

Nov 21, 2024

Nov 20, 2024

NeuroPace, Inc. (NPCE) Reports Q3 Loss, Tops Revenue Estimates - MSN

Nov 20, 2024

Nov 20, 2024

What Makes NeuroPace (NPCE) a New Buy Stock - MSN

Nov 20, 2024

Nov 18, 2024

Wall Street Analysts Believe NeuroPace (NPCE) Could Rally 54.34%: Here's is How to Trade - Yahoo Finance

Nov 18, 2024

Nov 18, 2024

NeuroPace FY2024 EPS Forecast Raised by Cantor Fitzgerald - Defense World

Nov 18, 2024

Nov 18, 2024

Cantor Fitzgerald Boosts Earnings Estimates for NeuroPace - MarketBeat

Nov 18, 2024

Nov 17, 2024

NeuroPace (NASDAQ:NPCE) Price Target Cut to $13.00 by Analysts at Wells Fargo & Company - Defense World

Nov 17, 2024

Nov 16, 2024

FY2024 EPS Estimates for NeuroPace Lifted by Leerink Partnrs - Defense World

Nov 16, 2024

Nov 15, 2024

NeuroPace FY2024 EPS Forecast Boosted by Leerink Partnrs - MarketBeat

Nov 15, 2024

Nov 14, 2024

NeuroPace Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 14, 2024

Nov 14, 2024

Here's What Analysts Are Forecasting For NeuroPace, Inc. (NASDAQ:NPCE) After Its Third-Quarter Results - Simply Wall St

Nov 14, 2024

Nov 14, 2024

Long NPCE: NeuroPace Inc. Q3 Earnings, 28% Revenue Growth, Nautilus Study Progress, and Breakout from $6-$7 Consolidation Signal Bullish Momentum - Invezz

Nov 14, 2024

Nov 14, 2024

How the (NPCE) price action is used to our Advantage - Stock Traders Daily

Nov 14, 2024

Nov 13, 2024

NeuroPace price target lowered to $13 from $15 at Wells Fargo - TipRanks

Nov 13, 2024

Nov 13, 2024

NeuroPace, Inc. (NASDAQ:NPCE) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 13, 2024

Nov 13, 2024

500: Something went wrong - Investing.com Canada

Nov 13, 2024

Nov 13, 2024

NeuroPace Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance - The Manila Times

Nov 13, 2024

Nov 12, 2024

NeuroPace, Inc. Reports Strong Q3 2024 Results - TipRanks

Nov 12, 2024

Nov 12, 2024

NeuroPace Inc.: Q3 Earnings Snapshot - San Francisco Chronicle

Nov 12, 2024

Nov 12, 2024

Neuropace earnings beat by $0.08, revenue topped estimates - Investing.com UK

Nov 12, 2024

Nov 11, 2024

Neuroscience Market Projected to Reach USD 50.2 Billion by 2032, Growing at a 4.0% CAGR – S&S Insider - GlobeNewswire Inc.

Nov 11, 2024

Nov 11, 2024

Earnings To Watch: NeuroPace Inc (NPCE) Reports Q3 2024 Result - Yahoo Finance

Nov 11, 2024

Nov 10, 2024

NeuroPace (NPCE) Set to Announce Earnings on Tuesday - Defense World

Nov 10, 2024

Nov 09, 2024

private equity firms who own 45% along with institutions invested in NeuroPace, Inc. (NASDAQ:NPCE) saw increase in their holdings value last week - Yahoo Finance

Nov 09, 2024

Nov 07, 2024

Does NeuroPace (NASDAQ:NPCE) Have A Healthy Balance Sheet? - Simply Wall St

Nov 07, 2024

Nov 06, 2024

NeuroPace submits RNS System study data to FDA By Investing.com - Investing.com Australia

Nov 06, 2024

Nov 05, 2024

NeuroPace (NPCE) Set to Announce Quarterly Earnings on Tuesday - MarketBeat

Nov 05, 2024

Nov 04, 2024

NeuroPace Announces FDA Submission of Three-Year Data from Post-Approval Study of the RNS System in Focal Epilepsy - ForexTV.com

Nov 04, 2024

Nov 04, 2024

NeuroPace submits RNS System study data to FDA - Investing.com India

Nov 04, 2024

Nov 03, 2024

How to Take Advantage of moves in (NPCE) - Stock Traders Daily

Nov 03, 2024

Nov 03, 2024

Analysts Set NeuroPace, Inc. (NASDAQ:NPCE) Target Price at $14.00 - Defense World

Nov 03, 2024

Oct 31, 2024

NeuroPace, Inc. (NASDAQ:NPCE) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Oct 31, 2024

Oct 29, 2024

Strength Seen in NeuroPace (NPCE): Can Its 5.1% Jump Turn into More Strength? - MSN

Oct 29, 2024

Oct 29, 2024

Deep Brain Stimulation Devices Market Growing Popularity & Emerging Trends | Medtronic, NeuroPace, LivaNova - openPR

Oct 29, 2024

Oct 28, 2024

KCK LTD.'s Strategic Reduction in NeuroPace Inc Shares - Yahoo Finance

Oct 28, 2024

Oct 28, 2024

Neuropace shareholder KCK Ltd. sells $1.22 million in stock By Investing.com - Investing.com South Africa

Oct 28, 2024

Oct 28, 2024

Neuropace shareholder KCK Ltd. sells $1.22 million in stock - Investing.com

Oct 28, 2024

Oct 28, 2024

Ltd. Kck Sells 223,991 Shares of NeuroPace, Inc. (NASDAQ:NPCE) Stock - MarketBeat

Oct 28, 2024

Oct 24, 2024

KCK LTD. Adjusts Stake in NeuroPace Inc - GuruFocus.com

Oct 24, 2024

Oct 24, 2024

Neuropace Inc sees $24,853 stock sale by major shareholder - Investing.com

Oct 24, 2024

Oct 24, 2024

Page 85 – Impact Investing - Equities News

Oct 24, 2024

Oct 23, 2024

Neuropace stock hits 52-week low at $5.66 amid market challenges - Investing.com Australia

Oct 23, 2024